Pharmaceuticals

The Department of the Army Medical Command has published a Special Notice regarding a sole source contract opportunity for FDA-approved radiopharmaceuticals. The notice announces the Medical Readiness Contracting Office-West's intent to award a firm-fixed-price contract exclusively to Lantheus Medical Imaging for Tc99m Generator and Xenon radiopharmaceuticals. This procurement falls under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and is being executed under the authority of 10 United States Code 3204(a)(1), which permits sole source awards when only one responsible source can satisfy agency requirements. The contract performance period is scheduled from October 1, 2025, to September 30, 2026, with an anticipated award date of September 15, 2025.

The primary objective of this Special Notice is to formally notify the contracting community of the government's intent to proceed with a non-competitive procurement for critical radiopharmaceutical supplies. The notice explicitly states that this is not a competitive proposal opportunity and establishes a deadline of July 25, 2025, for any responses or inquiries. The government has made clear that no capability briefings or telephonic inquiries will be accepted, maintaining sole discretion over whether to proceed with competition. Eligibility is effectively limited to businesses meeting the small business size standard of 1,300 employees for the pharmaceutical preparation manufacturing sector. The procurement represents a strategic decision by the Army Medical Command to ensure reliable access to essential radiopharmaceutical products through an established supplier relationship.